Thus far, although a meta-analysis demonstrated that 12-month trastuzumab treatment prolongs OS and DFS in women with early-stage HER2-positive breast cancer compared with shorter durations15, there is no study quantifying the association between shortened time and survival outcomes. This evidence concerns the gene ERBB2 and breast cancer.